Compare RJF & TEVA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | RJF | TEVA |
|---|---|---|
| Founded | 1962 | 1901 |
| Country | United States | Israel |
| Employees | N/A | N/A |
| Industry | Investment Bankers/Brokers/Service | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 31.4B | 30.2B |
| IPO Year | N/A | N/A |
| Metric | RJF | TEVA |
|---|---|---|
| Price | $163.57 | $28.37 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 12 | 8 |
| Target Price | ★ $181.00 | $27.00 |
| AVG Volume (30 Days) | 1.1M | ★ 11.4M |
| Earning Date | 10-22-2025 | 11-05-2025 |
| Dividend Yield | ★ 1.32% | N/A |
| EPS Growth | ★ 6.19 | N/A |
| EPS | ★ 10.30 | 0.62 |
| Revenue | $14,015,000,000.00 | ★ $16,776,000,000.00 |
| Revenue This Year | $13.65 | $4.74 |
| Revenue Next Year | $6.45 | $0.48 |
| P/E Ratio | ★ $15.84 | $46.12 |
| Revenue Growth | ★ 9.52 | 0.02 |
| 52 Week Low | $117.57 | $12.47 |
| 52 Week High | $177.66 | $28.68 |
| Indicator | RJF | TEVA |
|---|---|---|
| Relative Strength Index (RSI) | 60.05 | 79.96 |
| Support Level | $155.16 | $24.01 |
| Resistance Level | $157.68 | $26.96 |
| Average True Range (ATR) | 3.19 | 0.66 |
| MACD | 1.20 | 0.17 |
| Stochastic Oscillator | 88.13 | 91.97 |
Raymond James Financial is a diversified financial services firm that provides wealth management, investment banking, asset management, and capital markets services to individuals, corporations, and municipalities. The firm maintains an extensive catalogue of products and services across its business lines. However, the wealth management franchise generates the bulk of its revenues and earnings through a vast network of nearly 8,800 independent and employee-affiliated advisors, who collectively manage over $1.7 trillion in client assets as of fiscal year-end 2025. While Raymond James maintains a global footprint, the company derives over 90% of its revenue, and an even larger percentage of its operating income, from the United States.
Teva Pharmaceutical, based in Israel, is the leading generic drug manufacturer in the world. Teva derives half of its sales from North America and makes up a high-single-digit percentage of the total number of generic prescriptions in the US. It also has a significant presence in Europe, Japan, Russia, and Israel. Besides generics, Teva has a portfolio of innovative medicines and biosimilars in three main therapeutic areas: the central nervous system with Copaxone, Ajovy, and Austedo; respiratory with Qvar and ProAir; and oncology with Truxima, Herzuma, and Bendeka/Treanda. Teva also sells active pharmaceutical ingredients, offers contract manufacturing services, and owns Anda, a US-based generic and specialty drug distributor.